Role of Retinoid Receptors in the Prevention and Treatment of Breast Cancer

Overview

Journal J Mammary Gland Biol Neoplasia

Date 2000 Mar 8

PMID 10705921

Citations 8

Authors

L M Yang

K Wu

P Brown

Affiliations

Soon will be listed here.

Abstract

Retinoids are vitamin A-related compounds that have been found to prevent cancer in animals and humans. In this review, we discuss the role of retinoids and their receptors in the treatment and prevention of breast cancer. The retinoid receptors are expressed in normal and malignant breast cells, and are critical for normal development. In breast cells, when bound by retinoid hormones, these proteins regulate proliferation, apoptosis, and differentiation. The mechanism by which retinoids inhibit breast cell growth has not been completely elucidated, however, retinoids have been shown to affect multiple signal transduction pathways, including IGF-, TGFbeta-, and AP-1-dependent pathways. Retinoids have also been shown to suppress the growth and prevent the development of breast cancer in animals. These agents suppress tumorigenesis in carcinogen-treated rats and in transgenic mice, and inhibit the growth of transplanted breast tumors. These promising preclinical results have provided the rationale to test retinoids in clinical trials for the treatment and prevention of breast cancer. Several retinoids, including all trans retinoic acid and 9-cis retinoic acid, have been shown to have modest activity in the treatment of breast cancer, and these agents are now in clinical trials in combination with cytotoxic agents and anti-estrogens. Another retinoid, 4-HPR, is currently being tested in a human cancer prevention trial. Preliminary results suggest that 4-HPR may suppress breast cancer development in premenopausal women. Future clinical trials will focus on testing new synthetic retinoids that have reduced toxicity and enhanced therapeutic and preventive efficacy.

Citing Articles

Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention.

Muccio D, Atigadda V, Brouillette W, Bland K, Krontiras H, Grubbs C Curr Top Med Chem. 2016; 17(6):676-695.

PMID: 27320329 PMC: 9904082. DOI: 10.2174/1568026616666160617093604.

During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.

Salazar M, Ratnam M, Patki M, Kisovic I, Trumbly R, Iman M Breast Cancer Res. 2011; 13(1):R18.

PMID: 21299862 PMC: 3109587. DOI: 10.1186/bcr2827.

The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor.

Li Y, Shen Q, Kim H, Bissonnette R, Lamph W, Yan B Breast Cancer Res Treat. 2010; 128(3):667-77.

PMID: 20821348 PMC: 3444826. DOI: 10.1007/s10549-010-1083-9.

Retinoid-induced histone deacetylation inhibits telomerase activity in estrogen receptor-negative breast cancer cells.

Phipps S, Love W, White T, Andrews L, Tollefsbol T Anticancer Res. 2010; 29(12):4959-64.

PMID: 20044602 PMC: 2888005.

Expression analyses of nuclear receptor genes in breast cancer cell lines exposed to soy phytoestrogens after BRCA2 knockdown by TaqMan Low-Density Array (TLDA).

Satih S, Savinel H, Rabiau N, Fontana L, Bignon Y, Bernard-Gallon D J Mol Signal. 2009; 4:3.

PMID: 19442290 PMC: 2687443. DOI: 10.1186/1750-2187-4-3.

References

Veronesi U, De Palo G, Costa A, Formelli F, Marubini E, Del Vecchio M . Chemoprevention of breast cancer with retinoids. J Natl Cancer Inst Monogr. 1992; (12):93-7. View

Anzano M, Peer C, Smith J, Mullen L, Shrader M, Logsdon D . Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst. 1996; 88(2):123-5. DOI: 10.1093/jnci/88.2.123. View

Lee J, Newman R, Lippman S, Huber M, Minor T, Raber M . Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol. 1993; 11(5):959-66. DOI: 10.1200/JCO.1993.11.5.959. View

Bischoff E, Gottardis M, MOON T, HEYMAN R, Lamph W . Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res. 1998; 58(3):479-84. View

Hong W, Lippman S, Itri L, Karp D, Lee J, Byers R . Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990; 323(12):795-801. DOI: 10.1056/NEJM199009203231205. View

Cassidy J, Lippman M, Lacroix A, Peck G . Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. Eur J Cancer Clin Oncol. 1982; 18(10):925-8. DOI: 10.1016/0277-5379(82)90239-5. View

Toma S, Isnardi L, Riccardi L, BOLLAG W . Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res. 1998; 18(2A):935-42. View

Costa A, Malone W, Perloff M, Buranelli F, Campa T, DOSSENA G . Tolerability of the synthetic retinoid Fenretinide (HPR). Eur J Cancer Clin Oncol. 1989; 25(5):805-8. DOI: 10.1016/0277-5379(89)90124-7. View

Fraker L, Halter S, Forbes J . Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice. Cancer Res. 1984; 44(12 Pt 1):5757-63. View

10.

Sheikh M, Shao Z, Li X, Dawson M, Jetten A, Wu S . Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. J Biol Chem. 1994; 269(34):21440-7. View

11.

Chen J, Penco S, Ostrowski J, Balaguer P, Pons M, Starrett J . RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 1995; 14(6):1187-97. PMC: 398196. DOI: 10.1002/j.1460-2075.1995.tb07102.x. View

12.

Shalinsky D, Bischoff E, Lamph W, Zhang L, Boehm M, Davies P . A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res. 1997; 57(1):162-8. View

13.

Miller V, Benedetti F, Rigas J, Verret A, Pfister D, Straus D . Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol. 1997; 15(2):790-5. DOI: 10.1200/JCO.1997.15.2.790. View

14.

Li X, Shao Z, Sheikh M, Eiseman J, Sentz D, Jetten A . Retinoic acid nuclear receptor beta inhibits breast carcinoma anchorage independent growth. J Cell Physiol. 1995; 165(3):449-58. DOI: 10.1002/jcp.1041650302. View

15.

Sheikh M, Shao Z, Li X, Ordonez J, Conley B, Wu S . N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis. 1995; 16(10):2477-86. DOI: 10.1093/carcin/16.10.2477. View

16.

Sutton L, Warmuth M, Petros W, Winer E . Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemother Pharmacol. 1997; 40(4):335-41. DOI: 10.1007/s002800050666. View

17.

Grubbs C, Eto I, Juliana M, Whitaker L . Effect of canthaxanthin on chemically induced mammary carcinogenesis. Oncology. 1991; 48(3):239-45. DOI: 10.1159/000226935. View

18.

Costa A, Formelli F, Chiesa F, DeCensi A, De Palo G, Veronesi U . Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res. 1994; 54(7 Suppl):2032s-2037s. View

19.

Budd G, Adamson P, Gupta M, Homayoun P, Sandstrom S, Murphy R . Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res. 1998; 4(3):635-42. View

20.

Watson C, Medina D, Clark J . Estrogen receptor characterization in a transplantable mouse mammary tumor. Cancer Res. 1977; 37(9):3344-8. View